These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23580932)

  • 1. Formulation strategies for drug delivery of tacrolimus: An overview.
    Patel P; Patel H; Panchal S; Mehta T
    Int J Pharm Investig; 2012 Oct; 2(4):169-75. PubMed ID: 23580932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.
    Grinyó JM; Petruzzelli S
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1567-79. PubMed ID: 25407098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease.
    Olson KA; West K; McCarthy PL
    Pharmacotherapy; 2014 Jun; 34(6):e60-4. PubMed ID: 24700567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives.
    Oberbauer R; Bestard O; Furian L; Maggiore U; Pascual J; Rostaing L; Budde K
    Transplant Rev (Orlando); 2020 Apr; 34(2):100531. PubMed ID: 31955920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.
    Spencer CM; Goa KL; Gillis JC
    Drugs; 1997 Dec; 54(6):925-75. PubMed ID: 9421697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation.
    U.S. Multicenter FK506 Liver Study Group
    N Engl J Med; 1994 Oct; 331(17):1110-5. PubMed ID: 7523946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a self-microemulsifying drug delivery system of tacrolimus.
    von Suesskind-Schwendi M; Gruber M; Touraud D; Kunz W; Schmid C; Hirt SW; Lehle K
    Biomed Pharmacother; 2013 Jul; 67(6):469-73. PubMed ID: 23669280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis.
    Jindal S; Awasthi R; Singhare D; Kulkarni GT
    Med Hypotheses; 2020 Sep; 142():109838. PubMed ID: 32442677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in drug delivery to prolong allograft survival in lung transplant patients.
    Watts AB; Williams RO; Peters JI
    Drug Dev Ind Pharm; 2009 Mar; 35(3):259-71. PubMed ID: 18798087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical pharmacokinetics and therapeutic monitoring of tacrolimus].
    Garraffo R
    Therapie; 1997; 52(4):345-52. PubMed ID: 9437890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.
    Plosker GL; Foster RH
    Drugs; 2000 Feb; 59(2):323-89. PubMed ID: 10730553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.
    Peters DH; Fitton A; Plosker GL; Faulds D
    Drugs; 1993 Oct; 46(4):746-94. PubMed ID: 7506654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced oral bioavailability of tacrolimus in rats by self-microemulsifying drug delivery systems.
    Wang Y; Sun J; Zhang T; Liu H; He F; He Z
    Drug Dev Ind Pharm; 2011 Oct; 37(10):1225-30. PubMed ID: 21615281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of clinically relevant drug interactions associated with tacrolimus.
    Christians U; Jacobsen W; Benet LZ; Lampen A
    Clin Pharmacokinet; 2002; 41(11):813-51. PubMed ID: 12190331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug.
    Nassar T; Rom A; Nyska A; Benita S
    J Control Release; 2009 Jan; 133(1):77-84. PubMed ID: 18822327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.